The relationship between MMR deficiency and outcomes in EC patients is not well understood; different studies have provided conflicting results, some reporting better survival rates in women with MMR deficient EC, while others reporting this population to have poorer outcomes with higher rates of poor prognostic factors (e.g., advanced stage disease, deep myometrial invasion and LVSI). The gene discussed is MRC1; the disease is mismatch repair cancer syndrome 1.